Mode
Text Size
Log in / Sign up
N/A N=147 Randomized Supportive Care

Vidatalk Communication Application: Usability, Acceptability and Efficacy Study

Nonverbal Communication · Critical Illness

Enrolled (actual)
147
Serious AEs
0.0%
Results posted
Mar 2022
Primary outcome: Primary: Mean Daily Patient-reported Communication Difficulty Rating Using Single Item 0-4 Rating Scale — 3.10; 3.28 score on a scale — p=0.45

Study Design & Population

Study type
Interventional
Phase
N/A
Interventions
Aim 1 - VidaTalk - post-extubation (Other); Aim 2 - VidaTalk - intubated (Other); Aim 3 - VidaTalk tablet app (Device); Aim 3 - attention-control with non-VidaTalk tablet (Other)
Age
Adult, Older Adult · 18+ yrs
Sex
All
Sponsor
Ohio State University
Primary completion
Jun 2019

Outcome Measures

OutcomeResultp-value
PRIMARY
Mean Daily Patient-reported Communication Difficulty Rating Using Single Item 0-4 Rating Scale
3.10; 3.28 0.45
SECONDARY
Mean Patient Reported Anxiety Score Using Visual Analogue Scale
5.55; 6.02 0.55
SECONDARY
Mean Patient Frustration With Communication
3.14; 3.53 0.10
SECONDARY
Mean Daily Sedation Exposure
.01; .008; .84; .24 0.02 sig
SECONDARY
Ease of Communication at Extubation /ICU Discharge
23.19; 27.23 0.38
SECONDARY
Percentage of Patients Scoring in the "Calm" Range During Study Days on Richmond Agitation Sedation Score
81.48; 77.78 0.32
SECONDARY
Delirium/Coma -Free Days
8.26; 8.54 0.93
SECONDARY
Family Satisfaction With Care in the Intensive Care Unit FS-ICU
81.8; 92.4 0.07
SECONDARY
Electronic Visual Analogue Scale-validation Measure
SECONDARY
Patient Satisfaction With Care
4.45; 4.56 0.71
SECONDARY
Family Member Anxiety
9.14; 9.29; 8.67; 9.62; 4.86; 9.17 0.94
SECONDARY
Family Member Depression
5.86; 5.50; 5.78; 5.15; 7.43; 6.20 0.82
SECONDARY
Post-traumatic Stress Symptoms: Impact of Events Scale-revised (IES-R)
21.5; 30.5; 21; 27.5; 23; 26 0.26
SECONDARY
Family Communication Difficulty
28.67; 25.62; 33.67; 29.46
SECONDARY
Communication Task Error Rate
.45; 1.09; .09; 1.0; .273; 1.0
SECONDARY
Total Error Rate
0.30; 0.87
SECONDARY
Patient Satisfaction With Communication Task Ease
5.7; 6.7; 6.7; 6.7; 6.9; 5.8
SECONDARY
Observed Task Completion Time (in Seconds)
64.27; 117.45; 16.73; 80.0; 26.6; 74.0
SECONDARY
After-Scenario Questionnaire (ASQ) Score
18.2; 19.5; 20.3; 20.1; 20.7; 18.1
SECONDARY
System Usability Scale (SUS) -Adapted
82.5; 68.5
SECONDARY
Number of Participants That Responded "Yes" to Having Communication Difficulty at Extubation or ICU Discharge
0; 0; 14; 23; 0 0.05

Summary

This Phase II Small Business Technology Transfer Research (STTR) will deliver a comprehensive patient communication solution for communication-impaired patients in the intensive care unit that may help decrease days in delirium, decrease anxiety levels, and reduce sedation exposure which are proximal outcomes known to be associated with decreased mechanical ventilation days, shorter lengths of ICU and hospital stay, and lower healthcare cost. The primary goal of this Phase II STTR proposal is to further define user requirements and product specifications and develop a prototype of VidaTalk, a patient-centric, touch pad communication software, to provide mechanically ventilated (MV) patients an evidence-based solution for effectively communicating their needs to care providers and family. A secondary goal is to test the impact of the VidaTalk on clinical outcomes. This study will use mixed methods including observations and interaction with hospitalized patients as they use the VidaTalk tool, surveys and medical record data extraction, product evaluation and brief interview, satisfaction surveys with family members of ICU patients, and focus groups with Registered Nurses. Specific Aim 1. Develop a commercial prototype of VidaTalk that will include multilingual and customizable messages, compatibility with tablet devices, picture symbols, and integration with mobile communication devices. Specific Aim 2. Demonstrate usability with iterative user assessment testing in a clinical setting. Specific Aim 3. Test the clinical efficacy of VidaTalk via android application with MV patients by examining qualitative and quantitative endpoints in a clinical setting. Aim 3 hypothesis: MV patients using VidaTalk will demonstrate significant reductions in patient-reported communication difficulty and frustration, anxiety, sedation exposure, delirium/coma-free days, and improved patient and family satisfaction with ICU care compared to MV patients receiving attention-control (i.e., tablets with health education application). Specific Aim 4. Validation of electronic visual analogue scale, versus current standard paper scale. Specific Aim 5 a, b and c. Test the effect of the communication tablet (VidaTalk) on psychological symptoms in family caregivers.

Eligibility Criteria

Aim 1:

Inclusion Criteria

  • ≥18 years old
  • Able to communicate in English
  • Awake alert, responding appropriately to commands.
  • Normal (aided or unaided) hearing and vision
  • Able to control head, arm and hand movements
  • Physiologically stable and in no acute distress (per nurse report)

Exclusion Criteria

  • Pre-existing communication impairments
  • Diagnosis of severe dementia or brain injury
  • CAM-ICU positive for delirium
  • unresponsiveness or inattention

Aim 2:

Inclusion Criteria

  • ≥18 years old
  • Able to communicate in English
  • Awake alert, responding appropriately to commands.
  • Normal (aided or unaided) hearing and vision
  • Able to control head, arm and hand movements
  • Physiologically stable and in no acute distress (per nurse report)
  • Intubated via oral endotracheal or tracheal tube without speaking valve, receiving mechanical ventilation

Exclusion Criteria

  • Pre-existing communication impairments
  • Diagnosis of severe dementia or brain injury
  • CAM-ICU positive for delirium
  • unresponsiveness or inattention

Aim 3:

Inclusion Criteria

  • ≥18 years old
  • Able to communicate in English
  • Awake alert, responding appropriately to commands.
  • Normal (aided or unaided) hearing and vision
  • Able to control head, arm and hand movements
  • Physiologically stable and in no acute distress (per nurse report)
  • Intubated via oral endotracheal or tracheal tube without speaking valve, received mechanical ventilation during past 48 hours

Exclusion Criteria

  • Pre-existing communication impairments
  • Diagnosis of severe dementia or brain injury
  • CAM-ICU positive for delirium
  • unresponsiveness or inattention

Aim 5

Inclusion Criteria

  • Family caregivers of patient participants enrolled in Aim 3 as identified by the patient or self
  • >/=18 years old
  • Able to read and speak English
  • Non-professional, unpaid caregiver
  • Plans to visit at least 3 days/ week during ICU stay
  • Reliable telephone access (for follow-up assessment)

Exclusion Criteria

  • Age under 18 years
  • Unable to read and speak English
  • Severe uncorrected hearing loss
  • Self-reported diagnosis of dementia or Alzheimer's
  • Self-reported psychiatric disorder (bipolar disorder, schizophrenia) or substance abuse requiring inpatient treatment within the last 12 months
  • Unreliable telephone access
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT02921776). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search